Heron Therapeutics (HRTX) Other Non-Current Assets (2010 - 2026)

Heron Therapeutics has reported Other Non-Current Assets for 17 years, with the latest figure at $5.2 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Assets fell 17.13% year-over-year to $5.2 million; the trailing twelve-month figure through Mar 2026 stood at $5.2 million (down 17.13% YoY), and the FY2025 full-year result was $5.4 million, down 16.58% from the prior year.
• Other Non-Current Assets for Q1 2026 stood at $5.2 million, down from $5.4 million in the prior quarter.
• The five-year high for Other Non-Current Assets was $18.0 million in Q1 2022, with the low at $5.2 million in Q1 2026.
• Historically, Other Non-Current Assets has averaged $9.7 million across 5 years, with a median of $7.9 million in 2024.
• Annual changes were most pronounced in 2022 — Other Non-Current Assets soared 5095.66% — and 2023, when it sank 51.71%.
• Heron Therapeutics' Other Non-Current Assets stood at $15.7 million in 2022, then tumbled by 48.27% to $8.1 million in 2023, then retreated by 20.24% to $6.5 million in 2024, then fell by 16.58% to $5.4 million in 2025, then decreased by 3.72% to $5.2 million in 2026.
• The last three Other Non-Current Assets figures came in at $5.2 million (Q1 2026), $5.4 million (Q4 2025), and $5.9 million (Q3 2025), per Business Quant data.